Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Fayaz Ali Larik, Aamer Saeed, Urooj Muqadar, Hesham El-Seedi, Muhammad Faisal, Pervaiz Ali Channar & Haroon Mehfooz. (2017) The role of Lawesson's reagent in the total synthesis of macrocyclic natural products. Phosphorus, Sulfur, and Silicon and the Related Elements 192:5, pages 490-502.
Read now
Read now
Articles from other publishers (32)
Biykem Bozkurt, Ajith P. Nair, Arunima Misra, Claire Z. Scott, Jamal H. Mahar & Savitri Fedson. (2023) Neprilysin Inhibitors in Heart Failure. JACC: Basic to Translational Science 8:1, pages 88-105.
Crossref
Crossref
Olof Gidlöf. (2021) Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure. Frontiers in Physiology 12.
Crossref
Crossref
Nestor Vasquez, Spencer Carter & Justin L. Grodin. (2020) Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis. Current Heart Failure Reports 17:3, pages 67-76.
Crossref
Crossref
Laura Meems, Yang Chen & John C. BurnettJr.Jr.. 2018. Textbook of Nephro-Endocrinology. Textbook of Nephro-Endocrinology
163
171
.
Juan P. Salazar Adum & Rohit Arora. (2017) Role of Neprilysin Inhibitors in Heart Failure. American Journal of Therapeutics 24:6, pages e737-e743.
Crossref
Crossref
Carlos M. Ferrario & Adam E. Mullick. (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacological Research 125, pages 57-71.
Crossref
Crossref
Nicholas Phreaner & Barry H. Greenberg. (2017) Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. Current Emergency and Hospital Medicine Reports 5:2, pages 47-55.
Crossref
Crossref
Jesús Jurado‐Palomo & Teresa Caballero. 2017. A Comprehensive Review of Urticaria and Angioedema. A Comprehensive Review of Urticaria and Angioedema.
Yasbanoo Moayedi & Heather J. Ross. (2017) Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clinical Science 131:7, pages 553-566.
Crossref
Crossref
Yang Chen & John C BurnettJr.Jr.. (2017) Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. Clinical Chemistry 63:1, pages 108-115.
Crossref
Crossref
L. M. Lin, Y. Wu, M. F. Wu & J. X. Lin. (2016) Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration. Cardiovascular Drugs and Therapy 30:6, pages 623-633.
Crossref
Crossref
Ruth Hsiao & Barry Greenberg. (2016) Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy. Current Heart Failure Reports 13:4, pages 172-180.
Crossref
Crossref
Stuart B. Prenner, Sanjiv J. Shah & Clyde W. Yancy. (2016) Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Current Atherosclerosis Reports 18:8.
Crossref
Crossref
Elaine Nguyen, Erin R. Weeda & C. Michael White. (2016) A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. The Journal of Clinical Pharmacology 56:8, pages 936-947.
Crossref
Crossref
Lodi C.W. Roksnoer, Richard van Veghel, Marian C. Clahsen- van Groningen, René de Vries, Ingrid M. Garrelds, Usha M. Bhaggoe, Jeanette M.G. van Gool, Edith C.H. Friesema, Frank P.J. Leijten, Ewout J. Hoorn, A.H. Jan Danser & Wendy W. Batenburg. (2016) Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor–neprilysin inhibition compared with AT1 receptor blockade alone. Clinical Science 130:14, pages 1209-1220.
Crossref
Crossref
Brodie L Loudon, Hannah Noordali, Nicholas D Gollop, Michael P Frenneaux & Melanie Madhani. (2016) Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. British Journal of Pharmacology 173:12, pages 1911-1924.
Crossref
Crossref
A. J. Ansara, D. M. Kolanczyk & J. M. Koehler. (2016) Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Journal of Clinical Pharmacy and Therapeutics 41:2, pages 119-127.
Crossref
Crossref
Scott A. HubersNancy J. Brown. (2016) Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 133:11, pages 1115-1124.
Crossref
Crossref
Beatriz Wills, Leidy P. Prada, Alejandra Rincón & Andrés F. Buitrago. (2016) Inhibición dual de la neprilisina y del receptor de la angiotensina (ARNI): una alternativa en los pacientes con falla cardiaca. Revista Colombiana de Cardiología 23:2, pages 120-127.
Crossref
Crossref
Patrick T. Campbell & Sepehr Saberian. 2016. Pharmacologic Trends of Heart Failure. Pharmacologic Trends of Heart Failure
29
71
.
Jonathan Buggey, Robert J. Mentz, Adam D. DeVore & Eric J. Velazquez. (2015) Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. Journal of Cardiac Failure 21:9, pages 741-750.
Crossref
Crossref
Alan H. Gradman. (2015) LCZ696: The Next Step in Improving RAS Inhibition?. Current Hypertension Reports 17:5.
Crossref
Crossref
Orly Vardeny, Ryan Miller & Scott D. Solomon. (2014) Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. JACC: Heart Failure 2:6, pages 663-670.
Crossref
Crossref
Natalia Andrushko & Vasyl Andrushko. 2013. Stereoselective Synthesis of Drugs and Natural Products. Stereoselective Synthesis of Drugs and Natural Products
1
50
.
Thomas G. von LuederS. Jeson SangaralinghamBing H. WangAndrew R. KompaDan AtarJohn C. BurnettJrJrHenry Krum. (2013) Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation. Circulation: Heart Failure 6:3, pages 594-605.
Crossref
Crossref
Sarah Mangiafico, Lisa C. Costello-Boerrigter, Ingrid A. Andersen, Alessandro Cataliotti & John C. BurnettJrJr. (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal 34:12, pages 886-893.
Crossref
Crossref
David Wile. (2012) Diuretics: a review. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 49:5, pages 419-431.
Crossref
Crossref
Jamal El Bakali, Lucie Maingot, Julie Dumont, Helene Host, Akila Hocine, Nicolas Cousaert, Sandrine Dassonneville, Florence Leroux, Benoit Deprez & Rebecca Deprez-Poulain. (2012) Novel selective inhibitors of neutral endopeptidase: discovery by screening and hit-to-lead optimisation. MedChemComm 3:4, pages 469.
Crossref
Crossref
Melanie S. Glossop, Richard J. Bazin, Kevin N. Dack, David N.A. Fox, Graeme A. MacDonald, Mark Mills, Dafydd R. Owen, Chris Phillips, Keith A. Reeves, Tracy J. Ringer, Ross S. Strang & Christine A.L. Watson. (2011) Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:11, pages 3404-3406.
Crossref
Crossref
Christine L. Oltman, Eric P. Davidson, Lawrence J. Coppey, Travis L. Kleinschmidt, Brian Dake & Mark A. Yorek. (2011) Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. European Journal of Pharmacology 650:2-3, pages 556-562.
Crossref
Crossref
Dan Marquess. 2011. Third World Diseases. Third World Diseases
277
300
.
David C. PrydeGraham N. MawSimon PlankenMichelle Y. PlattsVivienne SandersonMartin CorlessAlan StobieChristopher G. BarberRachel RussellLaura FosterLaura BarkerChristopher WaymanPiet Van Der GraafPeter StaceyDebbie MorrenChristopher KohlKevin BeaumontSara CoggonMichael Tute. (2006) Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides. Journal of Medicinal Chemistry 49:14, pages 4409-4424.
Crossref
Crossref